EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease

Ayushi Nair iD, Alosh Greeny iD, Rajalakshmi Rajendran, Mohamed A Abdelgawad iD, Mohammed M Ghoneim iD, Roshni Pushpa Raghavan, Sachithra Thazhathuveedu Sudevan, Bijo Mathew, Hoon Kim iD

Pharmaceuticals · 19.01.2023 · 16 (2) · 147

DOI: 10.3390/ph16020147 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.01.2023. Verfasst von Ayushi Nair und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi 682041, India. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KIF1A-associated neurological diseases (KANDs) are a group of inherited conditions caused by changes in the microtubule (MT) motor protein KIF1A as a result of KIF1A gene mutations. Anterograde transport of membrane organelles is facilitated by the kinesin family protein encoded by the MT-based motor gene KIF1A. Variations in the KIF1A gene, which primarily affect the motor domain, disrupt its ability to transport synaptic vesicles containing synaptophysin and synaptotagmin leading to various neurological pathologies such as hereditary sensory neuropathy, autosomal dominant and recessive forms of spastic paraplegia, and different neurological conditions. These mutations are frequently misdiagnosed because they result from spontaneous, non-inherited genomic alterations. Whole-exome sequencing (WES), a cutting-edge method, assists neurologists in diagnosing the illness and in planning and choosing the best course of action. These conditions are simple to be identified in pediatric and have a life expectancy of 5–7 years. There is presently no permanent treatment for these illnesses, and researchers have not yet discovered a medicine to treat them. Scientists have more hope in gene therapy since it can be used to cure diseases brought on by mutations. In this review article, we discussed some of the experimental gene therapy methods, including gene replacement, gene knockdown, symptomatic gene therapy, and cell suicide gene therapy. It also covered its clinical symptoms, pathogenesis, current diagnostics, therapy, and research advances currently occurring in the field of KAND-related disorders. This review also explained the impact that gene therapy can be designed in this direction and afford the remarkable benefits to the patients and society.

Schlagwörter

Stichwörter der Autor:innen

KANDKIF1A genekinesin motor proteinmicrotubuleneurological disorder

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi 682041, India.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf 72341, Saudi Arabia.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
  • Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi 682 041, India.
  • Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea.

ORCID-Profile: Ayushi Nair, Alosh Greeny, Mohamed A Abdelgawad, Mohammed M Ghoneim, Hoon Kim

Zitieren

APA

Nair, A., Greeny, A., Rajendran, R., Abdelgawad, M. A., Ghoneim, M. M., Raghavan, R. P., Sudevan, S. T., Mathew, B., & Kim, H. (2023). KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease. Pharmaceuticals, 16(2), 147. https://doi.org/10.3390/ph16020147

Vancouver

Nair A, Greeny A, Rajendran R, Abdelgawad MA, Ghoneim MM, Raghavan RP, et al. KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease. Pharmaceuticals. 2023;16(2):147. doi:10.3390/ph16020147

BibTeX
@article{Nair2023,
  author = {Nair, Ayushi and Greeny, Alosh and Rajendran, Rajalakshmi and Abdelgawad, Mohamed A and Ghoneim, Mohammed M and Raghavan, Roshni Pushpa and Sudevan, Sachithra Thazhathuveedu and Mathew, Bijo and Kim, Hoon},
  title = {KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {147},
  doi = {10.3390/ph16020147}
}
Kostenlos starten →